xelia Oncology is developing safe and effective therapies for cancer patients using the body’s own immune system.
Investors 1
| Date | Name | Website |
| - | Stoic VC | stoicvc.co... |
Mentions in press and media 1
| Date | Title | Description |
| 17.02.2025 | Axelia Oncology Announces a Clinical Supply Agreement with Regeneron for Trial Evaluating AXA-042 in Combination with Libtayo® (cemiplimab) | Combination of First-in-Class Systemic TLR2/6 Agonist and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with Advanced Solid Tumours MELBOURNE, AUSTRALIA – 14th Feb 2025, Axelia Oncology announced today that it has entered into a c... |